The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months
over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral
density in premenopausal women with hormone receptor negative breast cancer and adjuvant
chemotherapeutic treatment